Drebin J A, Link V C, Weinberg R A, Greene M I
Proc Natl Acad Sci U S A. 1986 Dec;83(23):9129-33. doi: 10.1073/pnas.83.23.9129.
The neu oncogene encodes a 185-kDa transmembrane glycoprotein tumor antigen, termed p185. We have recently described a monoclonal antibody reactive with a cell surface domain of the p185 molecule. In vivo treatment with this anti-p185 monoclonal antibody was able to significantly inhibit the tumorigenic growth of neu-transformed NIH 3T3 cells implanted into nude mice. Such treatment had no effect on the tumorigenic growth of Ha-ras-transformed NIH 3T3 cells. Furthermore, anti-p185 antibody treatment was able to inhibit the growth of the rat neuroblastoma cells from which the neu oncogene was initially isolated. These results demonstrate that a monoclonal antibody reactive with the extracellular domain of an oncogene-encoded protein can exert a significant antitumor effect; such antibodies may prove useful in the therapy of certain malignancies.
神经癌基因编码一种185千道尔顿的跨膜糖蛋白肿瘤抗原,称为p185。我们最近描述了一种与p185分子的细胞表面结构域发生反应的单克隆抗体。用这种抗p185单克隆抗体进行体内治疗能够显著抑制植入裸鼠体内的neu转化的NIH 3T3细胞的致瘤生长。这种治疗对Ha-ras转化的NIH 3T3细胞的致瘤生长没有影响。此外,抗p185抗体治疗能够抑制最初分离出神经癌基因的大鼠神经母细胞瘤细胞的生长。这些结果表明,一种与癌基因编码蛋白的细胞外结构域发生反应的单克隆抗体能够发挥显著的抗肿瘤作用;此类抗体可能在某些恶性肿瘤的治疗中证明是有用的。